Reduction of Aβ levels in the Sprague Dawley rat after oral administration of the functional γ-secretase inhibitor, DAPT: A novel non-transgenic model for Aβ production inhibitors

Current Pharmaceutical Design

Volumn 12, Issue 6, 2006, Pages 671-676

  El Mouedden, Mohammed ^a   Vandermeeren, Marc ^a   Meert, Theo ^a   Mercken, Marc ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

APP transgenic mice; BACE1 inhibitors; ELISA; Monoclonal antibody; Presenilin 1 (PS1)

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE INHIBITOR; N [N (3,5 DIFLUOROPHENACETYL)ALANYL]PHENYLGLYCINE TERT BUTYL ESTER; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (17 42); AMYLOID BETA-PROTEIN (17-42); ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; DIPEPTIDE; ENZYME INHIBITOR; N (N (3,5 DIFLUOROPHENYLACETYL)ALANYL)PHENYLOGLYCINE T BUTYL ESTER; N-(N-(3,5-DIFLUOROPHENYLACETYL)ALANYL)PHENYLOGLYCINE T-BUTYL ESTER; PEPTIDE FRAGMENT; PROTEINASE; SECRETASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BODY FLUID; BRAIN TISSUE; BREEDING; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; ENCEPHALE ISOLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HYPOTHESIS; IN VIVO STUDY; MALE; MEDICAL ASSESSMENT; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RAT; REVIEW; SENILE PLAQUE; SPECIES DIFFERENCE; TIME; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; TREATMENT OUTCOME; WILD TYPE; ANIMAL; ARTICLE; BLOOD; BRAIN; CEREBROSPINAL FLUID; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; ECONOMICS; ENZYMOLOGY; HUMAN; METABOLISM; METHODOLOGY; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; BRAIN; DIPEPTIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDOPEPTIDASES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 33645310409     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775474233     Document Type: Review

References (19)

1. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001; 3: 75-80.
2. Braak H, Britak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-8.
3. Haass C, Selkoe DJ. Cellular processing of the beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993; 75: 1039-42.
4. Hardy J, The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci USA 1997; 94: 2095-7.
5. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 2002; 1: 859-66.
6. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice am healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10: 1317-24.
7. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001; 4: 231-2.
8. Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, Zhiang J, et al. BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 2003; 14: 81-8.
9. Wolfe MS. Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem 2001; 44: 2039-60
10. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76: 173-81.
11. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, et al. The gamma-secretase inhibitor N-[N-(3, 5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 2003; 305: 864-71.
12. Pype S, Moechars D, Dillen L, Mercken M. Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J Neurochem 2003; 84: 602-9.
13. Mercken M, Brepoels E, De Jong M, Laenen W, Raeymaekers P, Geerts H. Specific ELISA systems for the detection of endogenous human and rodent Aβ40 and Aβ. Neurobiol Aging 2000; 21: S41.
14. Vandermeeren M, Geraerts M, Pype S, Dillen L, Van Hove C, Mereken M. The functional γ-secretase inhibitor prevents production of amyloid β1-34 in human and murine cell lines. Neurosci Lett 2001; 315: 145-8.
15. Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, et al. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 1998; 18: 1743-52.
16. Beck M, Bigl V, Rossner S. Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo. Neurochem Res 2003; 28: 637-44.
17. Banks WA. Are the extracellular pathways a conduit for the delivery of therapeutics to the brain? Curr Pharm Design 2004; 10(12): 1365-70.
18. Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's Disease. Curr Pharm Design 2004; 10(3): 231-51.
19. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Design 2004; 10(13): 1469-92.